Amgen Inc.

(NASDAQ Global Select)
Back to all articles
Bullish +75

Amgen Earnings Call Highlights Growth, Pipeline Momentum

Drug approval Earnings report Guidance raised AI-generated analysis

πŸ“ˆ Amgen reported Q3 revenue of $10.4 billion, an 8% increase year-over-year, with six key growth drivers representing over 70% of total product sales.

πŸ’° Free cash flow reached $3.7 billion in the third quarter, providing substantial financial flexibility for R&D and capital investments.

πŸš€ Management raised the 2026 revenue guidance to $38.9-$39.7 billion and non-GAAP EPS to $22.90-$23.70, reflecting strong commercial momentum.

πŸ’Š Repatha sales climbed 37% to $1.1 billion, driven by a 60% increase in U.S. new-to-brand prescriptions and expanded patient access.

🦴 EVENITY revenue rose 39% to $751 million, supported by broader physician adoption and strong volume share retention in Japan.

🌬️ TEZSPIRE sales increased 43% to $538 million, fueled by growth in severe uncontrolled asthma and positive Phase III results in eosinophilic esophagitis.

🧬 UPLIZNA sales surged 191% to $451 million across all approved indications, with significant patient growth in generalized myasthenia gravis.

πŸ”¬ IMDELLTRA sales more than doubled to $406 million following positive Phase III data showing a 40% reduction in death risk versus chemotherapy.

🩸 Dazodalibep demonstrated significant improvement in systemic Sjogren's disease activity in Phase III, with benefits sustained through week 48.

πŸ’‰ Amgen completed enrollment in Phase III studies for MariTide in sleep apnea and cardiovascular outcomes, advancing toward potential launches.

πŸ“‰ TEPEZZA sales declined 6% to $526 million primarily due to a prior-year inventory build, though the company expects sequential growth in Q4.

⚠️ The company anticipates higher fourth-quarter expenses and $2 billion-$2.1 billion of other income/expense pressure in 2026 despite raised revenue targets.

Bullish Signals
  • Amgen reported Q3 revenue of $10.4 billion, an 8% year-over-year increase, with six key growth drivers accounting for over 70% of product sales.
  • Free cash flow reached $3.7 billion in the third quarter, demonstrating strong financial flexibility and operational efficiency.
  • Management raised the 2026 revenue guidance to $38.9-$39.7 billion and non-GAAP EPS to $22.90-$23.70, signaling confidence in future performance.
  • Repatha sales climbed 37% to $1.1 billion, driven by a 60% increase in U.S. new-to-brand prescriptions and expanded global patient treatment.
  • EVENITY revenue rose 39% to $751 million, supported by deepening physician adoption and strong market share retention in Japan.
  • TEZSPIRE sales increased 43% to $538 million, with Phase III results showing better remission outcomes in eosinophilic esophagitis.
  • UPLIZNA sales surged 191% to $451 million, supported by demand across all approved indications and expansion into 25 markets outside the U.S.
  • The innovative oncology portfolio grew 21% to $2.1 billion in sales, led by BLINCYTO growth of 27% to $496 million.
  • IMDELLTRA sales more than doubled to $406 million following positive Phase III data showing a 40% reduction in death risk versus chemotherapy.
  • The rare disease portfolio generated $1.6 billion in Q3 sales, up 21% year-over-year, reflecting successful international expansion and new approved uses.
Risk Factors
  • TEPEZZA sales declined 6% to $526 million in the third quarter, primarily due to a significant inventory build in the prior year complicating comparisons.
  • The company expects meaningful sequential increases in fourth-quarter operating expenses and anticipates $2 billion-$2.1 billion of other income/expense pressure in 2026.
  • Management cautioned that positive systemic Sjogren's results cannot be directly applied to the separate symptomatic Sjogren's study, requiring additional data for broader judgment.
  • Adoption of T-cell engagers like IMDELLTRA may face challenges outside specialist centers due to less experience managing cytokine release syndrome in community and urology sites.
  • Reimbursement for MariTide is expected to be more difficult outside the U.S., where treatment decisions are often consumer-driven rather than based on hard-endpoint outcomes.
Full Analysis
Amgen Inc (AMGN) reported strong third-quarter results with revenue rising 8% year-over-year to $10.4 billion, driven by a diverse portfolio where six key growth drivers accounted for over 70% of sales. The company highlighted robust cash generation, posting free cash flow of $3.7 billion in the quarter, and increased R&D spending by 11% alongside $600 million in capital expenditures to fuel innovation. Management maintained an optimistic tone, citing positive late-stage trial results and broad momentum across its therapeutic areas as key strengths. Amgen significantly raised its full-year 2026 outlook, projecting revenue between $38.9 billion and $39.7 billion and non-GAAP EPS in the range of $22.90 to $23.70. This guidance lift was supported by double-digit growth across multiple blockbuster products, including Repatha, EVENITY, and TEZSPIRE, which collectively demonstrated strong prescription volume increases and market share gains. The company also saw substantial growth in its rare disease portfolio, with UPLIZNA sales surging 191% to $451 million. The earnings call featured major positive updates on the clinical pipeline, including Phase III success for IMDELLTRA in small cell lung cancer and dazodalibep in Sjogren's disease. While management noted headwinds from a 6% decline in TEPEZZA sales due to prior-year inventory effects and anticipated higher fourth-quarter expenses, these were outweighed by the raised financial targets and successful commercial execution. The company emphasized its strategic focus on cardiovascular, oncology, immunology, and rare diseases while advancing biosimilar opportunities.